Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Utilization Review | 1 | 2016 | 19 | 0.540 |
Why?
|
| Coronary Disease | 3 | 2010 | 358 | 0.480 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 361 | 0.430 |
Why?
|
| Pharmaceutical Services | 2 | 2007 | 47 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1085 | 0.370 |
Why?
|
| Primary Prevention | 1 | 2010 | 115 | 0.350 |
Why?
|
| Formularies as Topic | 2 | 2007 | 5 | 0.330 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 212 | 0.320 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2007 | 7 | 0.300 |
Why?
|
| Managed Care Programs | 1 | 2007 | 45 | 0.290 |
Why?
|
| Disease Management | 1 | 2007 | 248 | 0.250 |
Why?
|
| Community Pharmacy Services | 2 | 2001 | 11 | 0.250 |
Why?
|
| Hypnotics and Sedatives | 1 | 2005 | 96 | 0.250 |
Why?
|
| Arteriosclerosis | 2 | 1996 | 137 | 0.240 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 648 | 0.240 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 438 | 0.240 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2005 | 91 | 0.230 |
Why?
|
| Piperazines | 1 | 2005 | 206 | 0.230 |
Why?
|
| Bacterial Vaccines | 2 | 1994 | 32 | 0.220 |
Why?
|
| Hypertension | 4 | 1995 | 1533 | 0.210 |
Why?
|
| Heartburn | 1 | 2001 | 46 | 0.190 |
Why?
|
| Peptic Ulcer | 1 | 2000 | 37 | 0.180 |
Why?
|
| Helicobacter Infections | 1 | 2000 | 40 | 0.180 |
Why?
|
| Helicobacter pylori | 1 | 2000 | 54 | 0.180 |
Why?
|
| Diuretics | 2 | 1994 | 96 | 0.170 |
Why?
|
| Insulin Resistance | 2 | 1998 | 241 | 0.170 |
Why?
|
| Calcium Channel Blockers | 3 | 1994 | 137 | 0.170 |
Why?
|
| Hyperinsulinism | 1 | 1998 | 23 | 0.160 |
Why?
|
| Humans | 31 | 2016 | 68549 | 0.150 |
Why?
|
| Pharmacists | 2 | 1995 | 125 | 0.140 |
Why?
|
| Health Promotion | 1 | 2000 | 407 | 0.140 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2016 | 6 | 0.140 |
Why?
|
| Haemophilus Vaccines | 2 | 1994 | 6 | 0.140 |
Why?
|
| Polysaccharides, Bacterial | 2 | 1994 | 31 | 0.130 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 49 | 0.130 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 1995 | 12 | 0.130 |
Why?
|
| Health Maintenance Organizations | 1 | 1995 | 22 | 0.130 |
Why?
|
| Blood Glucose | 1 | 1998 | 631 | 0.130 |
Why?
|
| Drug Industry | 1 | 1995 | 54 | 0.130 |
Why?
|
| Office Visits | 1 | 1995 | 83 | 0.120 |
Why?
|
| Triglycerides | 2 | 1992 | 184 | 0.120 |
Why?
|
| Blood Pressure Determination | 1 | 1995 | 151 | 0.120 |
Why?
|
| Viral Vaccines | 1 | 1994 | 17 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 848 | 0.120 |
Why?
|
| Amlodipine | 1 | 1994 | 31 | 0.120 |
Why?
|
| Immunization | 1 | 1994 | 86 | 0.120 |
Why?
|
| Enterococcus faecalis | 1 | 1993 | 6 | 0.110 |
Why?
|
| Streptomycin | 1 | 1993 | 12 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 659 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 1026 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1993 | 35 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1994 | 189 | 0.110 |
Why?
|
| Insulin | 1 | 2016 | 617 | 0.110 |
Why?
|
| Diphtheria Toxoid | 1 | 1992 | 5 | 0.100 |
Why?
|
| Vaccines, Synthetic | 1 | 1992 | 19 | 0.100 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1992 | 21 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1994 | 277 | 0.100 |
Why?
|
| Intermediate Care Facilities | 1 | 1991 | 2 | 0.100 |
Why?
|
| Drug Costs | 2 | 2007 | 87 | 0.090 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 161 | 0.090 |
Why?
|
| Skilled Nursing Facilities | 1 | 1991 | 30 | 0.090 |
Why?
|
| Vaccination | 1 | 1992 | 182 | 0.090 |
Why?
|
| Drug Utilization | 1 | 1991 | 119 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2001 | 424 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 1992 | 244 | 0.090 |
Why?
|
| Drug Evaluation | 3 | 2005 | 47 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2010 | 98 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 1995 | 824 | 0.080 |
Why?
|
| Piperonyl Butoxide | 1 | 1988 | 8 | 0.080 |
Why?
|
| Pyrethrins | 1 | 1988 | 6 | 0.080 |
Why?
|
| Lice Infestations | 1 | 1988 | 14 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 1991 | 247 | 0.080 |
Why?
|
| Family Practice | 3 | 1988 | 312 | 0.080 |
Why?
|
| Decision Making, Organizational | 1 | 2007 | 23 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 289 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 1990 | 497 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 177 | 0.070 |
Why?
|
| Azabicyclo Compounds | 1 | 2005 | 5 | 0.070 |
Why?
|
| United States | 4 | 2007 | 7338 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 503 | 0.060 |
Why?
|
| Hypokalemia | 1 | 1984 | 12 | 0.060 |
Why?
|
| Behcet Syndrome | 1 | 1984 | 5 | 0.060 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 1984 | 20 | 0.060 |
Why?
|
| Serum Sickness | 1 | 1983 | 1 | 0.060 |
Why?
|
| Metronidazole | 1 | 1983 | 28 | 0.050 |
Why?
|
| Limulus Test | 1 | 1982 | 1 | 0.050 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 1982 | 14 | 0.050 |
Why?
|
| Gonorrhea | 1 | 1982 | 50 | 0.050 |
Why?
|
| Quality of Life | 1 | 1990 | 1515 | 0.050 |
Why?
|
| Cholesterol | 2 | 1996 | 331 | 0.050 |
Why?
|
| Child, Preschool | 4 | 1994 | 3187 | 0.050 |
Why?
|
| Interprofessional Relations | 2 | 1988 | 188 | 0.050 |
Why?
|
| Female | 9 | 2010 | 38021 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 1995 | 339 | 0.040 |
Why?
|
| MEDLINE | 1 | 1998 | 9 | 0.040 |
Why?
|
| Drug Therapy | 2 | 1988 | 71 | 0.040 |
Why?
|
| Infant | 3 | 1994 | 2891 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1991 | 219 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 1998 | 203 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 1994 | 938 | 0.030 |
Why?
|
| Male | 6 | 2010 | 37283 | 0.030 |
Why?
|
| Pharmacy Administration | 1 | 1995 | 2 | 0.030 |
Why?
|
| Gingival Hyperplasia | 1 | 1994 | 4 | 0.030 |
Why?
|
| Measles Vaccine | 1 | 1994 | 3 | 0.030 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 1994 | 2 | 0.030 |
Why?
|
| Vaccines, Combined | 1 | 1994 | 8 | 0.030 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1994 | 4 | 0.030 |
Why?
|
| Bacterial Capsules | 1 | 1994 | 8 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 1994 | 12 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 1994 | 11 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1994 | 32 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 929 | 0.030 |
Why?
|
| Attitude of Health Personnel | 2 | 1995 | 442 | 0.030 |
Why?
|
| South Carolina | 4 | 1991 | 2752 | 0.030 |
Why?
|
| Adult | 7 | 1993 | 21379 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1993 | 70 | 0.030 |
Why?
|
| Gentamicins | 1 | 1993 | 68 | 0.030 |
Why?
|
| Risk Factors | 2 | 1994 | 5720 | 0.030 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1994 | 140 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1994 | 201 | 0.030 |
Why?
|
| Disease Progression | 1 | 1996 | 1037 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1993 | 215 | 0.030 |
Why?
|
| Niacin | 1 | 1992 | 12 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 1992 | 21 | 0.030 |
Why?
|
| Fees, Pharmaceutical | 1 | 1992 | 7 | 0.030 |
Why?
|
| Haemophilus Infections | 1 | 1992 | 15 | 0.030 |
Why?
|
| Haemophilus influenzae | 1 | 1992 | 16 | 0.030 |
Why?
|
| Animals | 3 | 1998 | 20880 | 0.030 |
Why?
|
| Random Allocation | 3 | 1989 | 442 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 1140 | 0.030 |
Why?
|
| Lipoproteins | 1 | 1992 | 161 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 1992 | 249 | 0.020 |
Why?
|
| Inservice Training | 1 | 1991 | 68 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 1996 | 696 | 0.020 |
Why?
|
| Weight Loss | 1 | 1992 | 319 | 0.020 |
Why?
|
| Magnesium Oxide | 1 | 1989 | 2 | 0.020 |
Why?
|
| Diet | 1 | 1992 | 514 | 0.020 |
Why?
|
| Permethrin | 1 | 1988 | 11 | 0.020 |
Why?
|
| Pediculus | 1 | 1988 | 8 | 0.020 |
Why?
|
| Pharmacy Service, Hospital | 1 | 1988 | 52 | 0.020 |
Why?
|
| Scalp | 1 | 1988 | 47 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1994 | 2455 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1990 | 402 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1988 | 304 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1995 | 2798 | 0.020 |
Why?
|
| Exercise | 1 | 1992 | 658 | 0.020 |
Why?
|
| Adolescent | 4 | 1989 | 8904 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 1992 | 805 | 0.020 |
Why?
|
| Hiccup | 1 | 1985 | 3 | 0.020 |
Why?
|
| Heart Failure | 1 | 1994 | 1179 | 0.020 |
Why?
|
| Haloperidol | 1 | 1985 | 95 | 0.020 |
Why?
|
| Dura Mater | 1 | 1984 | 23 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1984 | 30 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1991 | 2265 | 0.010 |
Why?
|
| Intracranial Pressure | 1 | 1984 | 58 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1984 | 151 | 0.010 |
Why?
|
| Vaginitis | 1 | 1983 | 21 | 0.010 |
Why?
|
| Pruritus | 1 | 1983 | 35 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1982 | 63 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1982 | 95 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1982 | 8 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1982 | 15 | 0.010 |
Why?
|
| Otitis Media | 1 | 1982 | 35 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 1981 | 11 | 0.010 |
Why?
|
| Role | 1 | 1981 | 25 | 0.010 |
Why?
|
| Child | 2 | 1988 | 6401 | 0.010 |
Why?
|
| Aged | 3 | 1994 | 14842 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 1989 | 17 | 0.010 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1988 | 3 | 0.010 |
Why?
|
| Diarrhea | 1 | 1989 | 63 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1989 | 112 | 0.010 |
Why?
|
| Physicians, Family | 1 | 1988 | 82 | 0.000 |
Why?
|
| Research | 1 | 1988 | 214 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1988 | 311 | 0.000 |
Why?
|
| Injections, Intramuscular | 1 | 1985 | 44 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1988 | 383 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1738 | 0.000 |
Why?
|
| Risk | 1 | 1982 | 563 | 0.000 |
Why?
|
| Acute Disease | 1 | 1982 | 658 | 0.000 |
Why?
|
| Recurrence | 1 | 1982 | 948 | 0.000 |
Why?
|
| Middle Aged | 1 | 1989 | 21119 | 0.000 |
Why?
|